Neurocrine Biosciences Reports Remarkable Growth in Q3 2025
Achieved Total Net Product Sales of $790 Million Representing 28% Year-Over-Year Growth
INGREZZA (valbenazine) Third-Quarter 2025 Net Product Sales of $687 Million Representing 12% Year-Over-Year Growth
CRENESSITY (crinecerfont) Third-Quarter 2025 Net Product Sales of $98 Million with 540 Total New Patient Enrollment Start Forms
Neurocrine Biosciences, Inc. (NASDAQ: NBIX) has announced an impressive performance for the third quarter of 2025, marking a substantial increase in total net product sales and further proving its strong impact in the neuroscience market. This achievement highlights the effectiveness of the company’s product portfolio and its commitment to advancing patient care.
Financial Highlights
The company recorded total net product sales of $790 million for Q3 2025, representing a 28% increase from the same quarter last year. This includes revenues from both INGREZZA and CRENESSITY, which continued to show robust demand and growth.
INGREZZA Growth
INGREZZA, used for the treatment of tardive dyskinesia, generated $687 million in net product sales this quarter. This reflects a significant 12% year-over-year increase, driven by strong patient demand and an uptick in new patient prescriptions.
CRENESSITY Launch Success
CRENESSITY contributed $98 million to the revenue, marking strong early demand with 540 new patient starts enrolled. This product, viewed as a first-in-class therapy for patients with classic congenital adrenal hyperplasia, is making a substantial impact in the market.
CEO Statement on Momentum
"Neurocrine's third quarter commercial results highlight the meaningful impact that INGREZZA and CRENESSITY are having on patients' lives," said Kyle W. Gano, Ph.D., Chief Executive Officer of Neurocrine Biosciences. "Our ongoing clinical trials for potential treatments for major depressive disorder and schizophrenia further position us for leadership in neuroscience innovation, advancing transformative therapies that can significantly improve patient outcomes."
Upcoming Developments
Neurocrine has initiated a second Phase 3 clinical trial for direclidine, investigating its efficacy in treating schizophrenia. The company has also been honored for presenting pivotal data from the Phase 2 SAVITRI trial regarding osavampator’s effects on depression severity.
Financial Outlook
Despite the operational and commercial successes, the company is looking ahead with continued investments in research and development. There has been an expanded investment in creating a solid base for its clinical portfolio. The outlook remains positive with expected revenue guidance reflecting ongoing support for INGREZZA and the recent launch of CRENESSITY.
Invitation for Investors
Neurocrine Biosciences will host its R&D Day, providing investors with insights into the ongoing research initiatives, pipeline advancements, and broader business strategies aimed at enhancing shareholder value.
Frequently Asked Questions
What was Neurocrine's total net product sales for Q3 2025?
Neurocrine reported total net product sales of $790 million for the third quarter of 2025.
How much did INGREZZA sell in the third quarter of 2025?
INGREZZA achieved net product sales of $687 million, a 12% increase compared to Q3 of the previous year.
What are the main drivers of growth for CRENESSITY?
The strong demand for CRENESSITY in treating classic congenital adrenal hyperplasia drove its net product sales to $98 million, with a significant number of new patients enrolled.
What future clinical initiatives is Neurocrine pursuing?
Neurocrine has initiated a second Phase 3 clinical trial for direclidine as a potential treatment for schizophrenia.
When will Neurocrine host its R&D Day?
Neurocrine's R&D Day will be held at the company’s headquarters, showcasing their leading innovations and future therapeutic endeavors.
